External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience EHDN 2024
Roche and Genentech at

EHDN 2024

September 12 - September 14
Strasbourg, France
ehdn.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Sep 14 / Roche and Genentech
Placebo response in HD: Comparing placebo arm in GENERATION HD1 vs Enroll-HD data
This presentation compares disease progression in the placebo arm of the GENERATION HD1 trial to the Enroll-HD cohort. and Roche's Natural History study observational study The main focus is on quantifying longitudinal changes in clinical scores and assessing their susceptibility to placebo response and the implications for optimizing clinical trial design and analysis in HD.
Neuroscience Huntington's Disease EHDN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 14 / Roche and Genentech
The conception, birth and toddler years of the European HD Network
This presentation describes the first 2-3 years of EHDN from its inception on a balcony of the hotel hosting the Gordon Research Conference in Tuscany in May 2003, to around 2006 when it moved into a more operational phase.
Neuroscience Huntington's Disease EHDN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 13 / Roche and Genentech
New fluid biomarker data from GENERATION HD1 and what it means for GENERATION HD2
This presentation includes the latest CSF fluid biomarkers results from GENERATION HD1 (YKL-40, total Tau (& ptau-181) & GFAP), related to neuroinflammation, neuronal death and astrocytic reactivity in HD. In GENERATION HD1 elevations in these biomarkers are avoided at the lowest exposures. The exposure group targeted in GENERATION HD2 has a favourable CSF fluid biomarker profile with NfL, YKL-40, total Tau & pTau-181 trending below placebo. In additiion, we provide an update on the iDMC recommendation to continue with the GENERATION HD2 study as planned after revieweing blinded data on safety, clinical, MRI & plasma NfL from 219 participants, with up to 5 doses of study treatment and an average time on treatment of 166 days.
Neuroscience Huntington's Disease EHDN-2024
08:45 AM
Duration 12mins Strasbourg, France
The conception, birth and toddler years of the European HD Network
Patrik Brundin
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 AM
Duration 2hrs Strasbourg, France
Longitudinal relationship between the Huntington’s Disease Digital Motor Score and clinical scales
Louis-Solal Giboin
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Strasbourg, France
Exposure dependent changes in CSF fluid biomarkers following tominersen treatment in GENERATION HD1
Yumi Yamamoto
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Strasbourg, France
Disease progression of individuals with Huntington’s disease assessed via the HD digital motor score
Ekaterina Volkova-Volkmar
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Strasbourg, France
Baseline clinical and imaging associations of fluid biomarkers in early manifest Huntington’s disease for the tominersen phase III trial GENERATION HD1
David Hawellek
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:45 AM
Duration 12mins Strasbourg, France
New fluid biomarker data from GENERATION HD1 and what it means for GENERATION HD2
Peter McColgan
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 12mins Strasbourg, France
Placebo response in HD: Comparing placebo arm in GENERATION HD1 vs Enroll-HD data
Marcelo Boareto
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.